OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
Accrued Liabilities
OSE Immunotherapeutics SA
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Accrued Liabilities
€2.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
40%
|
|
|
Valneva SE
PAR:VLA
|
Accrued Liabilities
€42.3m
|
CAGR 3-Years
35%
|
CAGR 5-Years
32%
|
CAGR 10-Years
23%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Accrued Liabilities
€3.2m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Accrued Liabilities
€3.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Accrued Liabilities
$5.7m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
9%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Accrued Liabilities
€5.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Accrued Liabilities?
Accrued Liabilities
2.7m
EUR
Based on the financial report for Dec 31, 2024, OSE Immunotherapeutics SA's Accrued Liabilities amounts to 2.7m EUR.
What is OSE Immunotherapeutics SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
40%
Over the last year, the Accrued Liabilities growth was 43%. The average annual Accrued Liabilities growth rates for OSE Immunotherapeutics SA have been -11% over the past three years , 9% over the past five years , and 40% over the past ten years .
You don't have any saved screeners yet